PET/CT monitoring of recurrence: Rohren and colleagues presents an SNMMI comment on this aspect of the recent American Society of Clinical Oncology Top Five List in Oncology as part of the Choosing Wisely Campaign.
Page 699
Folate receptor imaging: Maurer and colleagues focus on 99mTc-etarfolatide as a whole-body imaging agent and on the ways in which it may be used to direct folate receptor–targeted therapy.
Page 701
Thyroid cancer in children: Avram and Shulkin provide perspectives on current approaches to treatment in pediatric patients with differentiated thyroid cancer, including advances in optimal selection of patients for 131I therapy.
Page 705
89Zr-radiolabeled antibodies: Marquez and colleagues review the recent increase in preclinical and clinical investigations with this class of immuno-PET imaging agents and preview an article on glypican-3 targeting in this issue of JNM.
Page 708
Recurrent juvenile thyroid carcinoma: Mihailovic and colleagues analyze the probability of recurrence, prognostic factors, treatment, and outcomes in adolescents with differentiated thyroid cancer.
Page 710
PET/MR in astrocytic gliomas: Morana and colleagues investigate the diagnostic role, clinical contribution, and prognostic value of fused 18F-DOPA PET/MR images in pediatric supratentorial infiltrative astrocytomas.
Page 718
PET/MR and lung lesions: Rauscher and colleagues prospectively assess differences in quality, detection rate, size, and radiotracer uptake in pulmonary lesions using 18F-FDG PET/CT and PET/MR imaging.
Page 724
Whole-body aberrant gene expression detection: Sörensen and colleagues explore the clinical distribution, safety, dosimetry, and efficacy of 111In-ABY-025 in determining HER2 status in metastatic breast cancer.
Page 730
SUV and ADC in breast tumors: Baba and colleagues identify correlations between apparent diffusion coefficients from diffusion-weighted MR imaging and standardized uptake values from 18F-FDG PET imaging in breast cancer and look at their potential in diagnosis and prognosis.
Page 736
PET/CT and occult lymph node metastasis: Moon and colleagues investigate the value of 18F-FDG parameters of primary tumors in predicting occult lymph node metastasis in patients with clinically N0 esophageal squamous cell carcinoma.
Page 743
11C-acetate PET/CT in myeloma: Ho and colleagues compare the performance of 11C-acetate with that of 18F-FDG in PET/CT in multiple myeloma, including diagnostic accuracy, identification of high-risk patients, and monitoring of treatment response.
Page 749
SLN technique in prostate cancer: Rousseau and colleagues use laparoscopic surgery to validate the accuracy of an isotopic sentinel lymph node technique and correlate results with those from extended pelvic lymphadenectomy dissection in patients with localized prostate cancer.
Page 753
Diabetes and 18F-FDG hypometabolism: Roberts and colleagues explore the associations of type 2 diabetes with amyloid accumulation measured using 11C-Pittsburgh compound B and brain hypometabolism measured using 18F-FDG PET.
Page 759
Carrier-free 123I-iobenguane: Chin and colleagues report on a first-in-human phase 1 clinical study of a high-specific-activity carrier-free formulation of this agent for high-contrast, receptor-targeting SPECT applications.
Page 765
DAB4 and therapy monitoring: Al-Ejeh and colleagues characterize this murine monoclonal antibody in in vitro, human xenograft, and ex vivo analyses of clinical samples to determine suitability as a marker of cell death after cytotoxic treatment and a predictor of response.
Page 772
UTE bone maps for AC: Delso and colleagues assess the limitations of ultrashort-echo-time imaging for bone segmentation in MR-based attenuation correction of PET data in head and neck imaging.
Page 780
Radionuclides in nephrourology: Taylor, in part 2 of an educational overview, focuses on common clinical indications of suspected obstruction and renovascular hypertension and summarizes the status of radionuclide renal imaging in detection of infection and evaluation of the transplanted kidney.
Page 786
Zirconium PET for HCC: Sham and colleagues detail the use of an 89Zr-conjugated monoclonal antibody against glypican-3, a hepatocellular carcinoma–specific cell surface proteoglycan, for intrahepatic tumor localization with PET.
Page 799
PSMA as imaging reporter: Castanares and colleagues evaluate the use of prostate-specific membrane antigen as a genetic imaging reporter and compare its utility with that of 2 clinically established reporters.
Page 805
Melanoma theranostic agent: Qin and colleagues explore the use of 64CuCl2 as an agent for both PET imaging and radionuclide therapy of malignant melanoma in preclinical studies.
Page 812
Optical assessment of early response: Liu and colleagues report on studies designed to determine whether optical imaging of vascular endothelial growth factor expression can be an early biomarker for tumor response to gefitinib therapy.
Page 818
Imaging molecular events in RA: Zheng and colleagues describe the development of a SPECT/CT radiotracer for visualization of the complement receptor of the Ig superfamily in a mouse model of rheumatoid arthritis using radiolabeled Nanobodies.
Page 824
High-resolution antibody micro-SPECT: Branderhorst and colleagues test multipinhole SPECT with sub–half-millimeter resolution in intratumoral distributions of radiolabeled antibodies directed toward the epidermal growth factor receptor and compare the results with full 3D target expression assessed by immunohistochemistry.
Page 830
PET and I2-imidazoline targeting: Parker and colleagues describe development and initial studies in nonhuman primates with 11C-BU99008, a PET radioligand selective for I2-imidazoline binding sites, with potential for assessment of alterations in expression patterns of this protein in disease.
Page 838
64Cu dynamics in Menkes disease model: Nomura and colleagues use 64Cu-labeled PET imaging to investigate the effects of disulfiram on copper biodistribution in a mouse model of Menkes disease, an X-linked recessive disorder of copper metabolism.
Page 845
PET and aromatase imaging: Takahashi and colleagues report on development and initial studies of 11C-cetrozole, with potential for noninvasive PET quantification of aromatase expression and elucidation of the functional roles of aromatase in neurologic and emotional disorders.
Page 852
Novel 5HT4R PET tracer: Tavares and colleagues evaluate 18F-MNI698 as a potential PET radiotracer for imaging of serotonin 4 receptors in the brain, with promise in multiple brain disorders, including Alzheimer and Huntington diseases.
Page 858
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.